share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 4:持股变动声明-高管 Bruno Julianne
美股SEC公告 ·  05/24 16:20

Moomoo AI 已提取核心信息

CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been involved in a transaction with the company's stock on May 23, 2024. However, the details regarding the type of action, status, number of shares involved, nature of shares, transaction price, and the total value of shares after the transaction have not been disclosed. This information is crucial for investors to understand the implications of the insider's actions on their investment decisions.
CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been involved in a transaction with the company's stock on May 23, 2024. However, the details regarding the type of action, status, number of shares involved, nature of shares, transaction price, and the total value of shares after the transaction have not been disclosed. This information is crucial for investors to understand the implications of the insider's actions on their investment decisions.
CRISPR Therapeutics AG的首席运营官朱丽安·布鲁诺于2024年5月23日参与了与该公司股票的交易。但是,有关行动类型、地位、所涉股票数量、股票性质、交易价格和交易后股票总价值的详细信息尚未披露。这些信息对于投资者了解内部人士的行为对其投资决策的影响至关重要。
CRISPR Therapeutics AG的首席运营官朱丽安·布鲁诺于2024年5月23日参与了与该公司股票的交易。但是,有关行动类型、地位、所涉股票数量、股票性质、交易价格和交易后股票总价值的详细信息尚未披露。这些信息对于投资者了解内部人士的行为对其投资决策的影响至关重要。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息